XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.3
License Agreements - Novartis (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 179 Months Ended
Nov. 30, 2009
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Dec. 31, 2023
License Agreements              
Total revenues   $ 1,137,871,000 $ 919,025,000 $ 3,062,519,000 $ 2,682,308,000    
JAKAFI              
License Agreements              
Total revenues   741,181,000 636,252,000 2,018,993,000 1,898,605,000    
Novartis              
License Agreements              
Total revenues   0 5,000,000.0 0 5,000,000.0    
Novartis | JAKAFI | UNITED STATES              
License Agreements              
Total revenues   36,300,000 31,100,000 93,900,000 88,000,000.0    
Royalties payable   469,500,000   469,500,000   $ 469,500,000 $ 375,600,000
Novartis | JAKAVI              
License Agreements              
Total revenues   115,700,000 96,600,000 304,700,000 263,700,000    
Novartis | TABRECTA              
License Agreements              
Total revenues   $ 5,900,000 $ 4,100,000 $ 16,500,000 $ 13,100,000    
Maximum | Novartis | JAKAVI              
License Agreements              
Royalty payments on future global net sales (as a percent)       14.00%      
Minimum | Novartis | JAKAVI              
License Agreements              
Royalty payments on future global net sales (as a percent)       12.00%      
Development Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           157,000,000.0  
Development Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement $ 174,000,000.0            
Regulatory Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           345,000,000.0  
Regulatory Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement 495,000,000.0            
Commercialization Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 200,000,000.0  
Commercialization Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement 500,000,000.0            
Development and Regulatory Milestones | Maximum | Novartis | GVHD              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement $ 75,000,000.0